ライフサイエンスコーパス: cure rate

1 th mebendazole (P=0.02 for the comparison of cure rates).

2 peg-IFN/RBV was associated with a very high cure rate.

3 stimulus was associated with a reduced mouse cure rate.

4 n they are macroadenomas with a low surgical cure rate.

5 Parathyroidectomy achieved a 98% cure rate.

6 Primary endpoint was day 28 cure rate.

7 and currently available drugs exhibit a poor cure rate.

8 d-stage HL have contributed to an increasing cure rate.

9 in the irradiation field, resulting in a low cure rate.

10 hes will probably lead to an increase in the cure rate.

11 efficacy with >98% tumor regression and 60% cure rate.

12 erally accompanied by high mortality and low cure rate.

13 rvival benefit remains high and tends to the cure rate.

14 s was well-tolerated but resulted in limited cure rates.

15 ncrease remission rates and potentially also cure rates.

16 no significant improvement in recurrence and cure rates.

17 vedotin will hopefully further increase the cure rates.

18 ak immune tolerance, and increase functional cure rates.

19 ancer (TC) represents a malignancy with high cure rates.

20 ildren with cancer can achieve the same high cure rates.

21 ve rifampin to other antibiotics may improve cure rates.

22 current challenges to overcome for improved cure rates.

23 herapy or cystectomy, thus improving overall cure rates.

24 primary care increases treatment uptake and cure rates.

25 hat to treat appropriate targets and improve cure rates.

26 us (HIV)-infected patients results in modest cure rates.

27 rculosis may hasten TB treatment and improve cure rates.

28 e was no evidence that split dosing enhanced cure rates.

29 5 year follow-up while maintaining excellent cure rates.

30 are appropriate operations that achieve high cure rates.

31 The cure rate (16%) after complete CRS of colorectal periton

32 World, the combined placebo and cryotherapy cure rate (18%; 95% CI, 10%-31%) is likely to become the

33 Intention-to-treat analysis showed initial cure rates (2 months after treatment) of 22.2% (6 of 27)

34 the DNR control arm received high DNR doses (cure rate, 27.4% for IDA v 15.9% for DNR; P = .049).

35 for Vibramycin (95% CI for the difference in cure rates, -4.3% to 4.9%).

36 Splenectomy continues to provide the highest cure rate (60%-70% at 5+ years).

37 Patients infected with BI had lower cure rates (86.6%; 214 of 247) than those infected with

38 rative success (93.9 vs 95.6%, P = 0.073) or cure rates (96.2% vs 97.7%, P = 0.291) between nonlocali

39 ents, there was no significant difference in cure rates (97.8 vs 97.4%, P = 0.760) between nonlocaliz

40 ications (4 vs 0 complications; P = .32), or cure rates (98.6% vs 96.6%; P = .50).

41 ctomy is associated with improvements in the cure rate (99.4%) and the complication rate (1.45%) comp

42 In conclusion, the rapid cure rate achieved with these combinations is largely di

43 Cure rate after ASSP treatment was declining to about 84

44 The cure rate after parathyroidectomy was 98.2%.

45 The failure to cure rate after salvage surgery was 27.6% in high-volume

46 Cure rates after 6 months of follow-up were 31 of 40 (77

47 the same time period, evaluated biochemical cure rates after systematic lymph node dissection.

48 Furthermore, subjective cure rates, although initially high, also deteriorate ov

49 py in the intention-to-treat population, the cure rate among participants in the clindamycin group wa

50 famethoxazole treatment resulted in a higher cure rate among patients with a drained cutaneous absces

51 cutaneous leishmaniasis (CL), and different cure rates among New World CL have been obtained dependi

52 ohort studies in Bangladesh showed promising cure rates among patients with multidrug-resistant tuber

53 metastatic colorectal cancer and increasing cure rates among those with resectable disease.

54 ice at 25 mg/kg for 30 days cures, with 100% cure rate and 100% survival, the acute and chronic T. cr

55 new therapies are needed that offer a higher cure rate and a better safety profile, with convenience

56 e approach to this disease, providing a high cure rate and acceptable morbidity compared to non-PD re

57 a safe approach associated with an excellent cure rate and an overall low treatment burden despite a

58 F and miltefosine was tested to increase the cure rate and decrease the healing time.

59 was determined by means of assessment of the cure rate and egg-reduction rate.

60 Direct-acting antiviral drugs have a high cure rate and favourable tolerability for patients with

61 h acute promyelocytic leukaemia, with a high cure rate and less relapse than, and survival not differ

62 Patients with cancer had a lower cure rate and longer TTROD than patients without cancer.

63 tually develop targeted therapies to enhance cure rate and minimize acute and long-term toxic effects

64 ain the delicate balance between high cancer cure rate and overtreatment, which could potentially lea

65 refine current treatment and to improve the cure rate and quality of life of the patients.

66 Newer cancer therapy has increased cancer cure rate and survival time, but such benefit is not ful

67 odern treatment approaches is to improve the cure rate and, at the same time, minimize the long-term

68 ased therapy designed to maintain their high cure rates and avoid late effects.

69 treatment-shortening antibiotics to improve cure rates and curb the alarming emergence of drug resis

70 To increase cure rates and decrease long-term toxicity, there is gre

71 arc therapy promise to potentially increase cure rates and decrease toxicity due to increased accura

72 s (RAS) could hamper hepatitis C virus (HCV) cure rates and elimination efforts.

73 ks, with or without ribavirin, achieved high cure rates and had an excellent safety profile.

74 unotherapies promises to further advance the cure rates and improve quality of life of patients.

75 th cavitary TB have the potential to improve cure rates and reduce disease transmission.

76 The excellent cure rates and reduced toxicity risk support the use of

77 Dramatic improvements in the cure rates and survival outcomes for children with ALL h

78 therapy offers significantly improved viral cure rates and the possibility of shortened treatment du

79 dihydroartemisinin-piperaquine by increasing cure rates and thereby slowing resistance development.

80 ent of short and safe operations with a high cure rate, and recent studies have not only assessed the

81 providing histopathologic information, high cure rates, and acceptable cosmetic and functional outco

82 of disease and treatment for patients, poor cure rates, and high mortality bring distress to patient

83 For patients with early-stage disease, cure rates approach 100%.

84 ered an easy-to-treat infection, with higher cure rates ( approximately 70%) than other viral genotyp

85 Favorable RR-TB cure rates are achievable in this post-conflict setting

86 th fewer side effects and potentially higher cure rates are currently in development.

87 HCT for AML, but toxicity remains high, and cure rates are only 25% to 30% for relapsed AML.

88 For those with advanced-stage disease, cure rates are reportedly at least 75%.

89 The most effective treatments, with highest cure rates, are also cost-effective due to averted morta

90 The final cure rate at 180 days after the initiation of treatment

91 Cure rate at 3 months after therapy was 70%.

92 The clinical cure rate at test-of-cure for hospital-acquired cIAI was

93 The overall clinical cure rate at the 30-day visit with the intent-to-treat a

94 The primary efficacy variable was clinical cure rate at the test-of-cure visit (days 25-50).

95 itions for multidrug-resistant tuberculosis, cure rates at 120 weeks were 58% in the bedaquiline grou

96 excision, this approach may result in higher cure rates at a lower cost by allowing same-day reexcisi

97 Using survival analysis, uncorrected patient cure rates at day 28 were 75.7% (95% confidence interval

98 Clinical cure rates at test of cure (TOC, day 19-21) were high an

99 Clinical cure rates at test-of-cure were 80% (146 of 183) for mox

100 trate statistical noninferiority in clinical cure rates at the test-of-cure visit (24-32 days from st

101 statistical noninferiority (NI) in clinical cure rates at the test-of-cure visit (25-31 days from st

102 here were no differences in initial clinical cure rate between BI and non-BI strains in either group.

103 The difference in clinical cure rates between the groups was -0.80% (95% CI, -7.1%

104 Definitive chemoradiation results in high cure rates but causes long-term toxicity and may represe

105 addition of other therapies has not enhanced cure rates but identifying patients at greatest risk for

106 e fewest adverse effects and with acceptable cure rates but provided the shortest post-treatment prop

107 n HCV therapeutics have resulted in improved cure rates, but an HCV vaccine is not available and is u

108 Anti-incontinence surgery has high cure rates, but concerns about mesh tapes have resulted

109 Further increase in cure rate can be expected from the discovery of addition

110 High cure rates can be achieved in children with MDR tubercul

111 nt and follow-up protocols mean that overall cure rates can exceed 98% with fertility retention, wher

112 16F10 melanoma model, generating up to a 20% cure rate compared with 0% without AC-NPs.

113 provides superior anatomical and subjective cure rates compared with native tissue repair.

114 Cure rates, complication rates, pathologic findings, len

115 f the animals from death, but >5-fold higher cure rate could be achieved by combining imipenem and tw

116 Cure rate (CR) against S. stercoralis was the primary ou

117 The primary outcome was cure rate (CR) against T. trichiura, analyzed 13 to 20 d

118 Cure rates (CRs) and egg reduction rates (ERRs) were est

119 Cure rates (CRs, primary outcome) and egg reduction rate

120 Polymerase chain reaction (PCR)-adjusted cure rates declined from 100% in 2003 to 81.1% in 2013 a

121 Cure rates did not differ significantly between the two

122 The cure rate difference between the BI and non-BI patients

123 romise long-term health and to maintain high cure rates, dose-intensive chemotherapy with limited cum

124 Although cure rates exceed 80%, considerable unexplained interind

125 e promyelocytic leukemia (APL), resulting in cure rates exceeding 80%.

126 he most common childhood cancer, and despite cure rates exceeding 90% in children, it remains an impo

127 rug Administration approval, with remarkable cure rates exceeding 90%.

128 DAAs became available in January 2014, with cure rates exceeding 90%; only 51 000 veterans in VA car

129 ust our therapeutic approach and improve the cure rate for acute myeloid leukemia with FLT3/ITD.

130 Although the cure rate for childhood acute lymphoblastic leukemia (AL

131 Suburethral tapes have a higher cure rate for patients with predominant stress urinary i

132 is not associated with a decreased surgical cure rate for primary hyperparathyroidism.

133 ls for BMT in SCD could greatly increase the cure rate for this devastating disease.

134 ibiotics have now been shown to decrease the cure rates for anti-C. difficile therapy and increase th

135 Survival and cure rates for childhood cancers in Europe have greatly

136 With steadily improved cure rates for children with newly diagnosed acute lymph

137 Improved cure rates for esophageal and gastric cancer have increa

138 f protease inhibitors that will offer higher cure rates for genotype 1 patients and open the door for

139 that were given for 6 weeks resulted in high cure rates for HCV infection with excellent tolerability

140 We compared serological cure rates for human immunodeficiency virus (HIV)-negati

141 Cure rates for localized high-risk prostate cancers (PCa

142 treatments are needed to accomplish improved cure rates for multidrug-resistant and extensively drug-

143 Clinical and microbiologic cure rates for NGU were somewhat low and there was no si

144 Purpose Improvement of cure rates for patients treated with allogeneic hematopo

145 ing the hope of increasing the remission and cure rates for patients with acute myeloid leukemia.

146 Despite high cure rates for pediatric B-lineage acute lymphoblastic l

147 Cure rates for primary mediastinal large B-cell lymphoma

148 high for A. lumbricoides infections, whereas cure rates for T. trichiura infections are low.

149 he trials for CABP (FOCUS 1 and 2), clinical cure rates for the ceftaroline group were numerically hi

150 g administered orally as a single dose with cure rates for those treated with benzathine penicillin

151 or treatment of hospital-acquired pneumonia, cure rates for those with bacteremic S. aureus pneumonia

152 Miltefosine had demonstrated very good cure rates for visceral leishmaniasis (VL) in India, Nep

153 Microbial cure rates for WC2031 were 95.5% (95% CI, 92.3-98.8) ver

154 ormed a logistic meta-regression analysis of cure rates from all falciparum malaria treatment trials

155 ctions, although it is not likely to achieve cure rates >80% in macrolide-resistant strains, in a sim

156 Intensive chemotherapy regimens result in cure rates >85% in children and <50% in adults, warranti

157 remained the most cost-effective strategy at cure rates >88.4% and CDI recurrence rates <14.9%.

158 However, the pace of increasing the cure rate has slowed over the past 2 decades, and we hav

159 n saved compared with the pre-DOTS era, high cure rates have been achieved in most countries worldwid

160 Hepatitis C virus (HCV) cure rates have been similar in patients with and withou

161 in open urethroplasty with better long-term cure rates have fuelled the continuing debate as to whic

162 ral and parenteral therapies achieve similar cure rates; however, oral therapy avoids risks associate

163 the polymerase-chain-reaction (PCR)-adjusted cure rates (i.e., cure of the original infection; new in

164 The cure rate (ie, polymerase chain reaction-corrected adequ

165 ants [81.7%], respectively; P=0.73), and the cure rate in each active-treatment group was higher than

166 A previous study found a high cure rate in Mozambican children with uncomplicated Plas

167 The cure rate in the artemether-lumefantrine group was signi

168 The cure rate in the conventional remedial group (n = 107) w

169 The high cure rate in this prospective trial with a substantial n

170 -acting antivirals (DAAs) have led to a high cure rate in treated patients with chronic hepatitis C v

171 regimens that might boost the generally low cure rates in adults and subgroups of children with high

172 Cure rates in adults remain low and treatment is complic

173 responses and are thus far unable to affect cure rates in AML patients.

174 Despite these advances, cure rates in AML remain substantially unchanged in rece

175 n (CDI) in observational studies (>90%), but cure rates in clinical trials are lower.

176 founded, as demonstrated by 90% relapse-free cure rates in FMT treatment for recurrent Clostridioides

177 Notably, the clinical cure rates in ME patients with methicillin-resistant S.

178 cal radiotherapy and surgery achieve similar cure rates in muscle-invasive bladder cancer, but the ch

179 ndia and has achieved low mortality and high cure rates in nondefaulting children.

180 n procedures (90% and 35%), and hypertension cure rates in patients who underwent revascularization (

181 th the possibility of improving survival and cure rates in patients with breast cancer.

182 FMT was associated with lower cure rates in randomized trials than in open-label and i

183 urtimox, which have been associated with low cure rates in the chronic stage of the disease and which

184 efloquine-artesunate group; the PCR-adjusted cure rates in the intention-to-treat analysis were 94.2%

185 Secondary endpoints included clinical cure rates in the modified ITT population (231/250 [92.4

186 vorship issues, along with a need for better cure rates in the older patient, the improved survival o

187 The PCR-adjusted cure rates in the per-protocol analysis were 94.8% in th

188 important insights into the re-infection and cure rates in the two age groups.

189 SVR12 can be used effectively to determine "cure" rates in trials and in clinical practice.

190 lastic leukemia (ALL) is 80% to 90%, and the cure rate is 40% to 50%.

191 dectomy represents a standardized operation, cure rate is strongly associated with annual hospital ca

192 ion therapy of the brain has improved cancer cure rates, learning disorders and memory deficits are a

193 s with Hodgkin lymphoma, either by improving cure rates, minimizing toxicity, or both.

194 use a variant of survival analysis known as cure rate modelling to differentiate factors that influe

195 an intense regimen of chemotherapy yielding cure rates near 80%.

196 an intense regimen of chemotherapy yielding cure rates near 85%.

197 4 months after treatment, producing a final cure rate of 65%.

198 ffective therapy for DL, with a higher final cure rate of 75% observed when used in a total dose abov

199 icacy in CL caused by L. braziliensis with a cure rate of 75%.

200 th 4 obtaining cure, resulting in an overall cure rate of 90%.

201 Surgical resection carries a cure rate of 95% with the use of intraoperative parathyr

202 y invasive techniques (n = 23) resulted in a cure rate of 96% and a mean length of stay of 0.4 +/- 0.

203 compared to conventional exploration with a cure rate of 97.1% and a complication rate of 3.10%.

204 f antimalarial therapy was associated with a cure rate of 97.7% (95% confidence interval, 90.9 to 99.

205 Despite recent advances in the cure rate of acute lymphoblastic leukaemia (ALL), the pr

206 This appears to impact the cure rate of AF patients.

207 In Bihar state, India, the cure rate of antimonial compounds (eg, sodium stibogluco

208 o have a major effect on early death and the cure rate of APL.

209 newly diagnosed lymphomas and has an overall cure rate of approximately 60%.

210 The day 42 cure rate of asexual stages in the DHP + primaquine and

211 Clinical cure rate of BV at TOC was 59% (95% confidence interval

212 Although cure rate of childhood acute lymphoblastic leukemia (ALL

213 netics and pharmacogenetics) have pushed the cure rate of childhood acute lymphoblastic leukemia to n

214 gets is an important strategy to improve the cure rate of diffuse large B-cell lymphoma (DLBCL).

215 Imiquimod leads to an 80-100% cure rate of lentigo maligna; however, studies of invasi

216 ntimalarial potential was revealed by a 100% cure rate of malaria in mice with one administration of

217 ethal gynecologic malignancy with an overall cure rate of merely 30%.

218 lopment of effective treatments has led to a cure rate of more than 80% in children, creating opportu

219 varian carcinoma is a deadly disease, with a cure rate of only 30%.

220 The clinical cure rate of patients infected with the epidemic BI C. d

221 have led to a substantial improvement in the cure rate of patients suffering from T-cell acute lympho

222 The cure rate of T. trichiura infection was significantly hi

223 However, the cure rate of these patients is low and the course of the

224 mic BI C. difficile strain is lower than the cure rate of those infected with non-BI strains whether

225 im-sulfamethoxazole yields a higher clinical cure rate of uncomplicated cellulitis than cephalexin al

226 Despite the high cure rate of Wilms tumor, long-term survivors remain at

227 al agents (DAAs), are available that achieve cure rates of >90% in many patient populations including

228 diation before cell transplantation produced cure rates of 14% and 33%, respectively; whereas liver r

229 CI of VEGF121/rGel and PCI of bleomycin with cure rates of 40% and 33% respectively.

230 use models of breast and colon cancers, with cure rates of 40% and 60%, respectively.

231 an antibody directed against CD20, increases cure rates of adults with Burkitt leukemia from 40% to 8

232 s that these RIT approaches will improve the cure rates of allogeneic HCT for the thousands of patien

233 With cure rates of childhood acute lymphoblastic leukemia (AL

234 itial counseling on therapy emphasizes viral cure rates of currently 70%-80% as well as expected side

235 gents have revolutionized patient care, with cure rates of more than 90%.

236 malignancy with current therapy resulting in cure rates of only 60%.

237 There is an imperative need to improve the cure rates of patients diagnosed with invasive bladder c

238 nevirapine based, was associated with lower cure rates of TV for single-dose therapy.

239 erapy has been associated with very high HCV cure rates of up to 100%.

240 ure demonstrate no significant difference in cure rates or complications.

241 assignment remained associated with a higher cure rate (P = .04), together with younger age and favor

242 Six months after treatment, the final cure rate remained the same in both groups, without any

243 However, new therapies are needed to improve cure rates, shorten treatment duration, and improve tole

244 The comparative cure rate, small amount of drug administered, and tolera

245 re than five drugs can indeed achieve better cure rates than current recommended regimens.

246 ision, this surgical modality has much lower cure rates than Mohs micrographic surgery, likely due to

247 habitual exposure to carcinogens have lower cure rates than those that arise from infection with hum

248 In the present era of nearly 100% HCV cure rates thanks to direct-acting antivirals, these fin

249 isoniazid-resistant tuberculosis had a high cure rate, the cases of recurrence and acquired drug res

250 </= 1.00 mm thickness have a relatively good cure rate, the prognosis for patients with locally advan

251 lts, including fidaxomicin (similar clinical cure rates to vancomycin, with lower recurrence rates fo

252 The unadjusted cure rates, used as a measure of the post-treatment prop

253 ate the real-world ability of achieving high cure rates using patient navigation care models.

254 d for mechanical ventilation (MV), virologic cure rate (VQR), time to a negative viral polymerase cha

255 The cure rate was 100%, as evidenced by normalization of ser

256 The overall cure rate was 13.3%.

257 t 50% reduction of egg excretion and overall cure rate was 47% (IQR, 36%-70%) 6 weeks after the secon

258 The PCR-adjusted cure rate was 57.8% (95% confidence interval [CI], 45.4,

259 ing not responded to treatment, the clinical cure rate was 83% (124/150) for ciprofloxacin compared w

260 The clinical cure rate was 85% after the treatment.

261 The 210-day cure rate was 90% (95% confidence interval, 73-98%), sim

262 months after the end of treatment the final cure rate was 90.3%.

263 The initial cure rate was 95.8% (95% confidence interval [CI], 92.2-

264 The microbiological cure rate was 96% (123/128) for ciprofloxacin compared w

265 At the end of treatment the initial cure rate was 97.5% (intention to treat), and 6 months a

266 r ambulatory, minimally invasive techniques; cure rate was 99%.

267 The cure rate was comparable at day 42 in the ITT population

268 onfidence interval (CI) of the difference in cure rates was >-10%.

269 While cure rates were >95% in both treatment arms, the Pfkelch

270 Cure rates were 21 of 30 (70%; 95% confidence interval [

271 /mL or lower before reoperation, biochemical cure rates were 44% (59 of 133 patients) and 18% (12 of

272 Overall cure rates were 60.5% (46/76) for RZF 400 mg, 76.1% (35/

273 Clinical cure rates were 67% for lower UTI and 80% for upper UTI.

274 /61) for CAS; investigator-assessed clinical cure rates were 69.7% (53/76), 80.4% (37/46), and 70.5%

275 ESBL-producing Enterobacteriaceae, clinical cure rates were 87.5% (14/16) and 84.6% (11/13) in the e

276 olled in a pilot study of uncomplicated SAB, cure rates were 88% for telavancin and 89% for standard

277 ESBL-producing Enterobacteriaceae, clinical cure rates were 95.8% (23/24) and 88.5% (23/26) in the c

278 t genotype as non-treatment failures, day 28 cure rates were genotype adjusted to 91.1% (95% CI 84.1-

279 However, 28-day cure rates were low (45.9%), owing to parasite recrudesc

280 Cure rates were lower in randomized trials (139/216 pati

281 with CABP caused by S. pneumoniae, clinical cure rates were markedly higher in the ceftaroline treat

282 These agents can achieve very high cure rates when combined with pegylated interferon-beta

283 nd ECOG-PS more than 1 negatively influenced cure rate, which was higher in patients with favorable-r

284 The treatment challenge is to achieve a high cure rate while maintaining long-term renal function.

285 New therapies that maintain a high cure rate while reducing off-target toxicity are require

286 properties and is predicted to give improved cure rates while being recalcitrant to the development o

287 oncologists strive for maintaining excellent cure rates while minimizing toxic effects.

288 Novel targeted therapies to improve cure rates while minimizing toxicities are urgently need

289 The cure rate with albendazole (2.6%) and the egg-reduction

290 The clinical cure rate with ceftazidime-avibactam plus metronidazole

291 The ABC subtype has a approximately 40% cure rate with currently available therapies, which is w

292 o had not been cured with local therapy, the cure rate with systemic antileishmanial agents was 60%.

293 Clinical cure rates with ceftazidime-avibactam plus metronidazole

294 alysis by FMT delivery modality showed lower cure rates with enema than colonoscopy (WPR, 66.3% vs 87

295 itis C virus (HCV) treatments deliver higher cure rates with fewer contraindications, increasing dema

296 h IVA, when lesions are not amenable to high cure rates with surgery or radiation (RT).

297 centration >1 microg/mL, however, had higher cure rates with telavancin than with vancomycin.

298 reatment or combining drugs did not increase cure rates with these isolates.

299 Cure rates with this technology are high and complicatio

300 2.5 mg/kg/day for 28 days) resulted in a 59% cure rate, with lower systemic exposure than in adults.